Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

Joining us is the company Sanofi and Regeneron to talk to us more about COPD also known as Chronic Obstructive Pulmonary ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

Ted Koppel and his wife, Grace Anne Dorney Koppel — who was told she only had a few years left to live after her 2001 COPD ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD exacerbations in some patients whose symptoms aren’t adequately controlled with inhaled medicines.

The decision could significantly expand use of what is already one of the industry’s best-selling ... pulmonary disease, or COPD, that can’t be controlled with other medications.

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug ...

reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process. ICER isn't officially involved in the price negotiations introduced ...

However, the COPD segment is expected to see substantial growth due to advancements in treatment. By Medication Class: Key segments include combination drugs, inhaled corticosteroids (ICS), short ...

Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...